Merck's (MRK) Ifinatamab deruxtecan in adults with extensive-stage small cell lung cancer has been accepted for FDA priority review

Merck's Ifinatamab deruxtecan receiving FDA priority review is a notable advancement for its oncology portfolio, indicating the treatment's potential to address an urgent medical need in extensive-stage small cell lung cancer.

Newsquawk StaffPublished 13 Apr 2026, 11:20 UTCOn the live feed at 11:00 UTC — 5 more headlines followed before this page went public

Newsquawk headlinesUTC

11:08

India likely to receive below-average monsoon rains in 2026

11:04

Israeli PM Netanyahu says Israel supports Trump blockade on Iran

11:00

Merck's (MRK) Ifinatamab deruxtecan in adults with extensive-stage small cell lung cancer has been accepted for FDA priority review

10:54

Maersk (MAERSKB DC) says it will implement temporary cost reflective energy/fuel price adjustments on landslide transportation

10:52

"Israeli airstrike on the town of Al-Sama'iyah in southern Lebanon", Sky News Arabia reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free

Free. No signup, no card.

Context

This prioritization could enhance Merck’s position in the competitive pharmaceuticals market and likely support its stock performance, particularly if it leads to a successful market entry. Watch for market reactions, especially among biotech stocks and peers in the oncology space.

Equities · last 90 days

Recent headlines that moved markets

EQUITIES/8 Sept · 05:24 UTC

Saudi Energy Minister says a number of energy facilities and utilities were hit; are temporarily halting some operations.

Equity indices, after we published−0.3%

Modest downside seen across equity futures as energy prices tick higher.

EQUITIES/3 Sept · 04:54 UTC

North Korea stripped references to "peaceful unification" with South Korea from the charter of its ruling Workers' Party of Korea, according to Yonhap.

Equity indices, after we published−3.3%

EQUITIES/1 Sept · 16:17 UTC

Initial reports of an American attack on Iran, reports i24's Stein.

ES, after we published−0.2%

EQUITIES/26 Aug · 12:56 UTC

States and Meta (META) and agree to settle claims that platforms harmed children, according to a court filing; Meta agrees to pay a maximum of USD 16.68bln to states as part of deal

Market, after we published+2.6%

EQUITIES/8 Sept · 11:48 UTC

AstraZeneca (AZN LN) says Phase III tozorakimab data in COPD showed a 29%-34% reduction in exacerbations.

Market, after we published+1.0%

EQUITIES/7 Sept · 10:54 UTC

Saudi Aramco Jizan oil facilities were reportedly hit in new strikes, the FT reports citing sources; hit on Monday, damage is being assessed.

Equity indices, after we published−0.1%

Newsquawk Daily

Get both market opens in your inbox.

This note and the other one — the EU open and the US open, every business day, written by the desk. No account needed.

Related headlines

The whole workspace, free to try.

© 2026 Newsquawk. All rights reserved.